VIVITROL 380 mg + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Alcohol Dependence
Conditions
Alcohol Dependence
Trial Timeline
Jul 1, 2007 → Oct 1, 2009
NCT ID
NCT00511836About VIVITROL 380 mg + Placebo
VIVITROL 380 mg + Placebo is a approved stage product being developed by Alkermes for Alcohol Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT00511836. Target conditions include Alcohol Dependence.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00511836 | Approved | Completed |
Competing Products
20 competing products in Alcohol Dependence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| Lanifibranor | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| LY686017 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3537031 + Placebo | Eli Lilly | Phase 3 | 77 |
| AD04 (ondansetron) + Matching placebo | Adial Pharmaceuticals | Phase 3 | 69 |
| GODEX + Placebo | Celltrion | Phase 3 | 77 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 52 |
| ASP9831 + Placebo | Astellas Pharma | Phase 2 | 52 |
| ASP8062 + Placebo | Astellas Pharma | Phase 2 | 52 |
| LY686017 + Placebo | Eli Lilly | Phase 2 | 52 |
| Mazdutide + Placebo | Eli Lilly | Phase 2 | 52 |
| opioid receptor kappa antagonist | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2196044 + placebo | Eli Lilly | Phase 2 | 52 |